Actively Recruiting
A Study for HSK39775 in Participants With Solid Tumors
Led by Xizang Haisco Pharmaceutical Co., Ltd · Updated on 2024-03-18
243
Participants Needed
1
Research Sites
234 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research is designed to determine if HSK39775 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
CONDITIONS
Official Title
A Study for HSK39775 in Participants With Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older at screening
- Histological or cytological confirmation of advanced malignancy with failed or intolerant standard treatment, no standard therapy recognized, or standard therapy unavailable
- Eastern Cooperative Oncology Group performance status of 0 or 1
- Presence of evaluable disease
- Life expectancy of at least 12 weeks
- Adequate organ and bone marrow function as defined by protocol
- Female patients of childbearing potential must have a negative pregnancy test within 7 days before first dose and agree to use effective contraception during treatment and for 6 months after last dose
- Male patients must agree to use effective contraception during treatment and for 6 months after last dose
- Written informed consent obtained
You will not qualify if you...
- Known allergies to HSK39775 or its excipients
- Ineligible prior anticancer treatment as per protocol
- Use of continuous corticosteroids above 10 mg prednisone/day or equivalent within 4 weeks before first dose
- Receipt of live vaccine within 4 weeks before first dose
- Current participation in another investigational study
- Prior treatment with agents targeting the same pathway
- Unresolved toxicities from previous therapies above grade 1 or baseline
- Use of drugs with potential interactions within 4 weeks or 5 half-lives before first dose
- Major surgery within 4 weeks before first dose
- Central nervous system metastases with neurological symptoms
- Active hepatitis B or C infection
- History of immunodeficiency
- Clinically relevant cardiovascular disease as defined by protocol
- Inability to swallow study drug or gastrointestinal conditions affecting absorption
- Pregnancy or lactation
- Other conditions deemed unsuitable by investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fundan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032
Actively Recruiting
Research Team
Y
Yong Cao
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here